Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy

Henning Bundgaard130 enrolled

Overview

Objective The objective of the study is to assess the structural and functional cardiac effects of treatment with losartan in patients with hypertrophic cardiomyopathy (HCM). Design The study is a randomized, placebo-controlled, double-blinded trial. The follow-up period is 12 months. 130 patients with HCM will be included in predefined subgroups. Genotype positive relatives with borderline hypertrophy (\> 13 mm) will also be included. Data on individuals with borderline hypertrophy will be analysed separately from the rest of the cohort. Primary outcome Ventricular hypertrophy assessed as left ventricular mass and maximal wall thickness.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

130

Conditions

Hypertrophic Cardiomyopathy

Interventions

100 mg for 12 months.

PlaceboDRUG

100 mg for 12 months.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Hypertrophic cardiomyopathy * \> 18 years * Sinus rhythm Exclusion Criteria: * EF \< 50 % * Treatment with RAS-inhibitor * Contraindications to losartan

Locations (1)

Department of cardiology, Rigshospitalet.

Copenhagen, Denmark

Outcomes

Primary Outcomes

Hypertrophy of left ventricle

Left ventricular mass. Maximal wall thickness.

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.